ストックスクリーナーアプリを入手
0.8046
14.13%
0.0996
前日終値:
$0.705
開ける：
$0.75
24時間の取引高:
228.96K
Relative Volume:
1.63
時価総額：
$29.05M
収益：
-
当期純損益:
$-10.21M
株価収益率:
-1.3773
EPS:
-0.5842
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+8.88%
1か月 パフォーマンス:
+4.45%
6か月 パフォーマンス:
-1.66%
1年 パフォーマンス:
-67.16%
1日の値動き範囲:
$0.74
$0.8046
1週間の範囲:
$0.6701
$0.8046
52週間の値動き範囲:
$0.63
$2.5199
Neurosense Therapeutics Ltd Stock (NRSN) Company Profile
Compare NRSN vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NRSN
Neurosense Therapeutics Ltd
|
0.8046 | 29.05M | 0 | -10.21M | 0 | -0.5842 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Neurosense Therapeutics Ltd (NRSN) 最新ニュース
NRSN Q1'26 Earnings: EPS estimate is (0.08) USD - TradingView
Neurosense Therapeutics Ltd (NRSN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Neurosense Therapeutics Ltd - TradingKey
Neurosense Therapeutics Ltd (NRSN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Neurosense Therapeutics Ltd (NRSNW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Neurosense Therapeutics Ltd (NRSNW) Institutional Confidence - TradingKey
Neurosense Therapeutics Ltd (NRSNW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Neurosense Therapeutics Ltd (NRSNW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Neurosense Therapeutics Ltd (NRSNW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NeuroSense (NRSN) CFO acquires 250,000 shares in private placement - Stock Titan
Neurosense Therapeutics Ltd (NRSNW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Neurosense Therapeutics Ltd (NRSNW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Neurosense Therapeutics Ltd (NRSN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Neurosense Therapeutics Ltd (NRSN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Neurosense Therapeutics Ltd (NRSN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Neurosense Therapeutics Ltd (NRSN) Institutional Confidence - TradingKey
Neurosense Therapeutics Ltd (NRSNW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
NRSN Q1'26 Earnings: revenue estimate is 514.10K USD - TradingView
Neurosense Therapeutics Ltd (NRSN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
NeuroSense Therapeutics Ltd. (NRSN) Q2 2025 Earnings: Narrower-than-Expected Loss Marks Progress Amid Clinical-Stage OperationsPost-Announcement Reaction - newsline.com
NeuroSense Granted South Korean Patent Covering PrimeC Compositi - GuruFocus
NeuroSense Secures South Korean Patent for ALS Drug Candidate PrimeC - TipRanks
NeuroSense (Nasdaq: NRSN) secures South Korean patent protection for ALS therapy PrimeC - Stock Titan
NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS - PR Newswire
Roth MKM Maintains NeuroSense Therapeutics(NRSN.US) With Buy Rating, Maintains Target Price $3 - Moomoo
NeuroSense Therapeutics Wins Key Japanese Patent for ALS Drug PrimeC - TipRanks
Japanese patent extends PrimeC protection to 2042 for NeuroSense (NRSN) - Stock Titan
NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition - PR Newswire
Neurosense Therapeutics Ltd (NASDAQ: NRSN) Share Price, NRSN Stock News, NRSN Share Price & Updates - Kalkine
NeuroSense Therapeutics Advances Canadian Regulatory Talks on ALS Drug PrimeC - TipRanks
NeuroSense (NRSN) advances Health Canada discussions on PrimeC ALS regulatory path - Stock Titan
NRSN Q2 2025 Earnings: EPS Beat Signals Progress Amid Development StageFinancial Health Score - newsline.com
NRSN Q2 2025 Earnings: Narrower-than-Expected Loss Fails to Lift SharesDividend Increase Stocks - The Legal Advocate
NeuroSense Therapeutics (NRSN) Faces 4.5% Decline—Key Support at $0.78 Holds the LinePrice Action Signals - The Legal Advocate
NeuroSense Therapeutics (NRSN) Slides 3.94%, Pivots Near Key Support at $0.82VWAP Deviation - newsline.com
NeuroSense Therapeutics (NRSN) Edges Higher, Testing Resistance at $0.95PCR Moving Average - The Legal Advocate
NeuroSense trades close to 90 cents as next $1 Nasdaq threshold comes into view - Bez Kabli
Amyotrophic Lateral Sclerosis (ALS) Market Set for Significant - openPR.com
NRSN Q2 2025 Earnings: Narrower Loss Surprises, Shares Gain on Cost DisciplineFinal Results - The Legal Advocate
NeuroSense Therapeutics (NRSN) Slides 4.56% as Support Levels Are TestedExpert Market Insights - Newser
OutSee Selected for Discovery Award from Longitude Prize on ALS to Accelerate AI-Based Target Discovery - Yahoo Finance
TradingKey - TradingKey
NRSN (NeuroSense Therapeutics) Q2 loss narrows 6.9% more than expected, but investors await pipeline catalyst update.Expert Verified Trades - newser.com
NeuroSense Secures Insider-Led $600,000 PIPE at Premium Share Price - The Globe and Mail
NeuroSense Announces Pricing of Insider-Led PIPE Financing - The Malaysian Reserve
NeuroSense (Nasdaq: NRSN) insiders lead $600K PIPE financing at premium - Stock Titan
NeuroSense Therapeutics Ltd. announced that it expects to receive $0.6 million in funding - marketscreener.com
NeuroSense Therapeutics Transitions Chief Medical Officer to Advisory Role Ahead of Key PrimeC Milestones - The Globe and Mail
NeuroSense (NRSN) CMO steps down but stays on as advisor for PrimeC - Stock Titan
Niva Russek Blum Net Worth (2026) - GuruFocus
Ferenc Tracik Net Worth (2026) - GuruFocus
Neurosense Therapeutics Ltd (NRSN) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.44%
大文字化:
|
ボリューム (24 時間):